All news

Amdocs (DOX) Lands VEON Deal, Is The Stock Still Undervalued?

Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash

Amdocs (DOX) recently secured a 10-year technology agreement with VEON, which involves modernizing VEON's operations and integrating QazCode's AI capabilities into Amdocs' aOS telecom platform. Despite a recent stock rebound, Amdocs' year-to-date performance remains down, though many analysts consider it undervalued with a fair value of $82.03 against a current price of approximately $60.25. The company exhibits strong recurring revenue streams and a disciplined capital allocation strategy, but faces risks if telecom spending slows or GenAI investments do not yield profitable contracts.

Read original source

DOX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.